AxoGen, Inc. (AXGN) Set to Announce Earnings on Tuesday
AxoGen, Inc. (NASDAQ:AXGN) is set to release its earnings data after the market closes on Tuesday, October 31st. Analysts expect AxoGen to post earnings of ($0.06) per share for the quarter.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The company had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $14.40 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 46.2% on a year-over-year basis. On average, analysts expect AxoGen to post $-0.33 EPS for the current fiscal year and $-0.09 EPS for the next fiscal year.
Shares of AxoGen, Inc. (AXGN) opened at 20.00 on Tuesday. The firm’s market cap is $664.80 million. AxoGen, Inc. has a 12-month low of $7.65 and a 12-month high of $20.40. The firm’s 50-day moving average is $18.82 and its 200-day moving average is $15.74.
In other AxoGen news, Director Robert James Rudelius sold 16,143 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $18.00, for a total value of $290,574.00. Following the transaction, the director now directly owns 43,273 shares of the company’s stock, valued at approximately $778,914. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.33% of the company’s stock.
A number of equities analysts have issued reports on the company. Leerink Swann reaffirmed an “outperform” rating and issued a $23.00 target price (up from $22.00) on shares of AxoGen in a research report on Saturday, September 30th. Roth Capital reaffirmed a “buy” rating and issued a $21.00 target price (up from $18.00) on shares of AxoGen in a research report on Tuesday, September 12th. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $18.00 target price on shares of AxoGen in a research report on Monday, August 21st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.40.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.